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INTRODUCTION
Lysine biosynthesis in fungi, euglena, and certain arch-
aebacteria occurs through the a-aminoadipate pathway.1
Enzymes in the first steps of this pathway have been pro-
posed as potential targets for the development of antifun-
gal therapies, as they are absent in animals but are
conserved in several pathogenic fungi species, including
Candida, Cryptococcus, and Aspergillus.2 One potential
antifungal target in the a-aminoadipate pathway is the
third enzyme in the pathway, homoisocitrate dehydro-
genase (HICDH), which catalyzes the divalent metal-
dependent conversion of homoisocitrate to 2-oxoadipate
(2-OA) using nicotinamide adenine dinucleotide
(NAD1) as a cofactor.1
HICDH belongs to a family of b-hydroxyacid oxidative
decarboxylases that includes malate dehydrogenase, tar-
trate dehydrogenase, 6-phosphogluconate dehydrogenase,
isocitrate dehydrogenase (ICDH), and 3-isopropylmalte
dehydrogenase (IPMDH). ICDH and IPMDH are well-
characterized enzymes that catalyze the decarboxylation
of isocitrate to yield 2-oxoglutarate (2-OG) in the citric
acid cycle and the conversion of 3-isopropylmalate to 2-
oxoisovalerate in the leucine biosynthetic pathway,
respectively.3 Recent structural and biochemical studies
of HICDH reveal that this enzyme shares sequence, struc-
tural, and mechanistic homology with ICDH and
IPMDH.3–7 To date, the only published structures of
HICDH are from the archaebacteria Thermus thermophi-
lus (TtHICDH).6,8 Fungal HICDHs diverge from
TtHICDH in several aspects, including their thermal sta-
bility, oligomerization state, and substrate specificity,
thus warranting further characterization. To gain insights
into these differences, we determined crystal structures of
a fungal Schizosaccharomyces pombe HICDH (SpHICDH)
as an apoenzyme and as a binary complex with the addi-
tive tripeptide glycyl-glycyl-glycine (GGG) to 1.55 A˚ and
1.85 A˚ resolution, respectively. Finally, a comparison of
the SpHICDH and TtHICDH structures reveal differences
in their active sites that help explain the variations in
their respective substrate specificities.
MATERIALS ANDMETHODS
Cloning, expression, and purification
Full length HICDH encoded by the Lys121 gene in
S. pombe was amplified from the genomic clone
SPAC31G5.04 (Sanger Institute) and was subcloned into
a modified pET15b N-terminal 6xHIS-tag expression vec-
tor (Novagen) that contains a tobacco etch virus protease
cleavage site. The enzyme was overexpressed in the
Rosetta 2 strain (EMD Biosciences) by induction with
0.1 mM isopropyl b-D-1-thiogalactopyranoside at 228C
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for 16 h. Cells were resuspended in 50 mM sodium phos-
phate, pH 7.0, 500 mM NaCl, 5 mM b-mercaptoethanol
and were lysed with lysozyme followed by sonication.
Soluble enzyme was purified on a Talon (Clontech)
Co(II) column, and the 6xHIS tag was removed by incu-
bating with tobacco etch virus protease during dialysis
overnight against 50 mM sodium phosphate, pH 7.0, 150
mM NaCl, and 5 mM b-mercaptoethanol. The His-
tagged protease was removed by passing the sample over
a second Talon Co(II) column. SpHICDH was further
purified by gel filtration via isocratic elution with 50 mM
sodium phosphate, pH 7.0, 150 mM NaCl, and 1 mM
tris(2-carboxyethyl)phosphine on a Superdex 200 column
(GE healthcare). The protein was concentrated to
100–120 mg/mL (A280, e 517,420) and stored at 2808C.
Crystallization, data collection,
and structure determination
Crystals of SpHICDH were initially obtained by vapor
diffusion in a condition with 0.2M lithium acetate and
20% (w/v) PEG 3350. The Additive Screen HT
(Hampton Research) was used to determine that the
addition of 30 mM GGG improved crystal quality. Opti-
mization was performed at 208C in hanging drops com-
posed of 1.5 lL of 25 mg/mL SpHICDH, 1.5 mM 2-OA,
60 mM GGG as an additive and 1.5 lL crystallization so-
lution (0.22M lithium acetate and 18% (w/v) PEG 3350).
SpHICDH was also crystallized by hanging drop vapor
diffusion using 1 lL of 15–24 mg/mL SpHICDH, 2 mM
MgCl2, 6.6 mM 2-OA, and 2 mM NAD
1 in 1 lL 0.1–
0.25M lithium acetate, 12–16% PEG 3350. Crystals were
cryoprotected in their crystallization solution supple-
mented with 20% glycerol and subsequently frozen in
liquid nitrogen. Diffraction data were collected at LS-
CAT, beamline 21ID-G at the Advanced Photon Source
(Argonne National Labs), and data sets were integrated
and scaled using HKL20009 (Table I). A model of
SpHICDH was generated in Chainsaw10 from the
sequence alignment of SpHICDH and TtHICDH and the
coordinates of the TtHICDH structure (PDB 1X0L),6
which was subsequently used as a search model for mo-
lecular replacement in MOLREP.11 The model of
SpHICDH bound to GGG was built in Coot12 and
refined in REFMAC13 using TLS refinement.14 This
structure was used as a model for molecular replacement
for SpHICDH apoenzyme crystallized in the presence of
MgCl2, 2-OA, and NAD
1, which was built and refined as
described for the SpHICDH-GGG complex. The final
models were validated using Molprobity15 (Table I).
Root mean square deviations (RMSDs) were calculated
for Ca atoms using SSM Superpose in Coot.12 A simu-
lated annealing omit map of GGG was generated in
CNS16, and structural figures were created using MacPy-
MOL (The PyMOL Molecular Graphics System, Schro¨-
dinger, LLC.)
RESULTS AND DISCUSSION
Overall structure of SpHICDH
The crystal structures of SpHICDH apoenzyme and
complex with GGG were determined by molecular
replacement to 1.55 A˚ and 1.85 A˚, respectively (Table I).
The quaternary structure of SpHICDH consists of do-
main-swapped monomers [Fig. 1(A)] with density
observed for residues 5–360 and 4–360 of each monomer
in the apoenzyme and residues 5–362 of monomer A
and 5–53 and 57–359 of monomer B in the GGG-bound
complex. Each SpHICDH monomer is composed of a
large domain (residues 1–101 and 266–362), a small
domain (residues 102–129 and 156–265), both of mixed
a/b topology, and a clasp domain17 forming an antipar-
Table I
Data Collection and Refinement Statistics
SpHICDH
(apoenzyme)
SpHICDH
(GGG complex)
Data collection
Beamline 21-ID-G 21-ID-G
Space group P21 P21
Cell dimensions
a, b, c, () 52.85, 94.45, 76.08 53.24, 92.86, 75.47
b (o) 106.6 106.7
Wavelength () 0.97856 0.97856
Resolution ()a 25.0–1.55 (1.61–1.55) 20.0–1.85 (1.89–1.85)
Rmerge (%)
b 5.5 (45.9) 7.2 (41.5)
I/rI 30.2 (2.9) 22.1 (2.7)
Total reflections 713,906 380,206
Unique reflections 103,345 60,681
Redundancy 6.9 (4.3) 6.3 (3.9)
Completeness (%) 99.3 (94.2) 99.5 (94.7)
Refinement
Resolution range () 24.86–1.55 19.70–1.85
No. of reflections 97,599 56,698
No. of atoms 6084 5761
Protein atoms 5524 5371
Ligand/Glycerol 2/60 26/24
Water atoms 500 340
Rwork/Rfree
c 18.8/21.5 19.3/23.0
Average B-factors (2)
Overall 22.1 26.5
Protein 22.2 26.7
Ligand/Glycerol –/24.6 43.8/32.6
Water 20.9 21.5
RMSDs
Bond length () 0.012 0.014
Bond angles (o) 1.409 1.413
MolProbity scored 1.32 1.49
Percentilee 96th 95th
Ramachandran favored (%) 97.3 97.2
Ramachandran allowed (%) 2.7 2.8
Ramachandran outliers (%) 0 0
aValues in parentheses are for the highest-resolution shell.
bRmerge 5
P
hkl
P
j |Ij 2 I |/
P
hkl
P
j Ij where I is the mean intensity of reflection
hkl.
cRwork 5
P
hkl kFo| 2 |Fck /
P
hkl |Fo|; Rfree 5 5.1% of the total reflections.
d0.42574 3 log(11clashscore) 1 0.32996 3 log(11max(0,pctRotOut-1)) 1
0.24979 3 log(11max(0,100-pctRamaFavored-2)) 1 0.5
eFor structures with a resolutions  0.25 A˚ of the resolution of each SpHICDH
structure. 100th percentile is the best; 0th percentile is the worst.
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allel b-sheet at the dimer interface (residues 130–156)
[Fig. 1(A)]. The secondary structure of a monomer of
SpHICDH adopts a modified Rossmann fold17 with 10
b-strands (b1–b5 and b8–b12) creating a mixed parallel
and antiparallel b-sheet [Fig. 1(B)]. The remaining two
b-strands (b6–b7) compose the clasp domain, which
interacts with the adjacent monomer. Additional interac-
tions at the dimer interface are predominantly mediated
through the formation of a four-helix bundle between a7
and a8 from both monomers. This fold is homologous
to other b-hydroxyacid oxidative decarboxylases includ-
ing ICDHs (RMSDs 1.77 A˚ and 2.68 A˚ for PDB entries
1AI2 and 2QFV, respectively),18,19 IPMDHs (RMSDs
1.92 A˚ and 1.84 A˚ for PDB codes 1IPD and 1A05,
respectively),20,21 and TtHICDH (RMSD 1.23 A˚ for
PDB entry 1X0L).6
A structural comparison of SpHICDH with Escherichia
coli ICDH (EcICDH) in a complex with isocitrate and
NADPH,18 Thiobacillus ferrooxidans IPMDH (TfIPMDH)
bound to isopropylmalate,20 and TtHICDH6 illustrates
similarities and differences among these enzymes [Fig.
1(C)]. Each of these enzymes adopts a closed conforma-
tion. The closed and open forms of these enzymes refer
to the width of the NADH binding pocket, which is
located in a cleft between the large and small domains
below the active site [Fig 1(A)]. For example, the
EcICHD apoenzyme has been crystallized in the open
and closed states, whereas substrate-bound EcICHD
adopts a closed form, which is a result of a 168 rota-
tion of the large domain relative to the small domain
that narrows the NADH binding cleft17,22. The major
difference between SpHICDH and other b-hydroxyacid
Figure 1
Crystal structure of SpHICDH (A) Ribbon diagram of a homodimer of SpHICDH with the large domain, small domain, and clasp domain of
monomer A depicted in dark blue, light blue, and cyan, and of monomer B in dark orange, orange, and light orange, respectively. (B) Cartoon
representation of the secondary structure of a monomer of SpHICDH with secondary structure elements labeled. (C) Ribbon diagram illustrating
the superimposition of a monomer of SpHICDH [colored as described for monomer A in (A)] with those of EcICDH (PDB ID 1AI2, light
orange), TfIPMDH (PDB entry 1A05, orange), and TtHICDH (PDB code 1X0L, gray). Rearrangement of the 310-helix between the SpHICDH and
TtHICDH apoenzyme structures is circled.
Structure of Homoisocitrate Dehydrogenase
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oxidative decarboxylases is the conformation of the clasp
domain and the loop region following b4. The 310-helix
preceding the clasp also differs in its orientation between
SpHICDH and TtHICDH apoenzyme (discussed below).
Active site of SpHICDH
The active site of SpHICDH is located in a cleft between
the small and large domains of one monomer and also
contains residues from the small domain of the neighbor-
ing monomer. [Fig. 1(A)]. Although 2-OA, NAD1, and
Mg(II) were included in the crystallization condition, the
ligands and metal ion were not observed in the electron
density maps. Despite their absence, the apoenzyme’s
active site adopts a conformation homologous to the
closed state EcICDH bound to isocitrate and NAD1,18
Saccharomyces cerevisiae mitochondrial NADP-dependent
ICDH (ScICDH) in a complex with isocitrate,19 and
TfIPMDH bound to isopropylmalate.20 Similarly, the
TtHICDH apoenzyme also displays a closed state6 [Fig.
1(C)], suggesting that HICDH may not undergo an exten-
sive active site conformational change as observed for
IPMDH23,24 and ICDH enzymes.17,19,22 Alternatively,
the crystallization conditions for the HICDH enzymes
may simply force the enzyme into a closed state. Addi-
tional structures of the HICDH apoenzyme and complexes
with substrates are needed to resolve this question.
The residues in the active site responsible for substrate
binding and catalysis have been identified through
homology with ICDH and IPMDH and by biochemical
characterization of S. cerevisiae HICDH (ScHICDH).3 A
lysine–tyrosine pair composed of Lys-1960 and Tyr-133 in
SpHICDH (the prime (0) denotes a residue in the adja-
cent monomer) have been implicated in the acid–base
catalyzed reaction that converts homoisocitrate to 2-OA,
based on kinetic studies of ScHICDH [Fig. 2(A)].5 Addi-
tionally, three conserved aspartate residues (Asp2320,
Asp256, and Asp260) have been proposed to coordinate
the divalent metal ion necessary for catalysis.6 Because
SpHICDH adopts a closed conformation in the absence
of substrates, its structure can be superimposed with that
of an EcICDH-isocitrate complex25 to gain insight into
HICDH substrate recognition. Homoisocitrate is pre-
dicted to bind in a similar orientation as isocitrate, with
its C1 carboxylate group and 2-hydroxyl groups coordi-
nated to the active site metal ion. Three structurally con-
served arginine residues (Arg97, Arg107, and Arg126)
further stabilize the substrate through interactions with
its C1 and C6 carboxylate groups [Fig. 2(A)]. To visualize
the binding position of the second substrate, NAD1, a
product complex of HICDH bound to 2-OA, NADH,
and Mg(II) was modeled by aligning the active site resi-
dues to that of a product complex of mitochondrial
ScICDH bound to NADPH and 2-OG19 [Fig 2(B)]. The
modeled NADH binds in the active site cleft, adjacent to
the product 2-OA, and is flanked by a9 and the loop
between b3 and a4 of one monomer and a7 of the adja-
cent monomer [Figs. 1(B) and 2(B)]. The modeled
NADH fits well into the active site cleft of SpHICDH;
however, there is a clash between the ribose hydroxyl
groups of the nicotinamide mononucleotide of NADH
and Ser81 located in the b3-a4 loop of the protein, sug-
gesting that a conformational change of this loop is
required for coenzyme binding. In summary, the struc-
tural alignments illustrate that the active site residues of
SpHICDH responsible for substrate binding and catalysis
are conserved with the residues in other b-hydroxyacid
oxidative decarboxylases.
Unexpectedly, we observed that the tripeptide additive
GGG binds in the active site of SpHICDH. Two conserved
arginine residues (Arg97 and Arg126), which are proposed
to interact with homoisocitrate, form contacts with GGG
through a network of direct and water-mediated hydrogen
bonds [Fig. 2(C)]. The tripeptide is further stabilized by
hydrogen bonding to the backbone atoms of residues
Ser85, Val87, and Gly89, which are located in the loop
between b3 and a4. Additional hydrogen bonds occur
between the a-amine group of GGG and Glu285 and
Pro286. Together, these interactions orient the GGG tri-
peptide into a similar location as the modeled NADH and
2-OA products [Supporting Information Fig. S1]. Specifi-
cally, the backbone carbonyl of the second glycine is nearly
superimposable with the modeled nitrogen in the ring of
the nicotinamide moiety of NADH. Additionally, the C-
terminal carboxylate of GGG is positioned between the
amide nitrogen in the nicotinamide group of NADH and
the C1 carboxylate of 2-OA, respectively.
Comparison of SpHICDH to TtHICDH
A comparison of the SpHICDH and TtHICDH struc-
tures reveals some key differences between the fungal and
archaeal enzymes. First, the two enzymes exhibit distinct
oligomerization states. SpHICDH eluted as a homodimer
in size exclusion chromatography (data not shown) and
crystallized in the same oligomerization state (Table I).
In contrast, TtHICDH functions as a homotetramer, with
the clasp domain of two dimers forming hydrophobic
intersubunit interactions.6,7 This tetramerization state is
presumably unique to archaeal HICHDs and may
enhance the thermostability of the enzyme, as a mutation
that disrupts tetramerization exhibits a lower thermal
inactivation temperature.6 Moreover, the active site con-
formation differs between SpHICDH and TtHICDH
apoenzyme despite their homologous structures [Figs.
1(C) and 2(D)]. In TtHICDH, the active site adopts a
nonproductive conformation in which Tyr125 is flipped
out of the active site cleft [Fig. 2(D)]. This observation
lead Miayzaki et al. to speculate that either substrate
binding is coupled to a conformational change in the
active site or the TtHICDH structure represents a non-
physiologically relevant structure, possibly induced by the
S.L. Bulfer et al.
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low pH of the crystallization condition.6 Conversely, in
SpHICDH, the corresponding tyrosine (Tyr133) is orien-
tated in a catalytically competent conformation due to a
shift of the 310 helix toward b6 and b7 of the clasp do-
main. In a recent study, the structure of TtHICDH in
complex with a designed inhibitor is reported.8 Similar to
SpHICDH, the catalytic tyrosine (Tyr125) is flipped
inward and interacts with the inhibitor, indicating that it
is important for catalysis, and possibly substrate binding.
These finding suggest that the SpHICDH active site adopts
a conformation that is conducive to substrate binding,
whereas the nonproductive configuration observed in the
TtHICDH apoenzyme structure may be a consequence of
the crystallization condition. Further structural studies of
HICDH substrate and product complexes are needed to
ascertain the extent of the conformational changes that
occur in the active site during ligand binding.
In addition to variations in their oligomerization state
and active site conformation, the substrate specificities of
the fungal and archaeal HICDHs also differ. TtHICDH
utilizes both isocitrate and homoisocitrate as substrates,
whereas yeast HICDHs display greater specificity for
homoisocitrate versus isocitrate.4,7,26 Mutagenesis stud-
ies in TtHICDH determined that substrate specificity is
governed by a key active site residue, Arg85 in TtHICDH
or Val94 in SpHICDH, which occupy the same position
Figure 2
Active site of SpHICDH (A) Stick diagram of the active site of apo-SpHICDH with isocitrate and Mg(II) modeled from a superimposition with
isocitrate dehydrogenase (PDB ID 5ICD). Isocitrate is modeled in stick configuration with yellow carbon atoms and the Mg(II) ion is shown as a
green sphere. (B) A model of the product complex of SpHICDH. A surface representation of SpHICDH monomer A (orange) and monomer B
(blue) illustrates the NAD1 binding cleft. The NADH and 2-OA products were modeled by aligning apo-SpHICDH with a product complex of
ScICDH bound to NADPH and 2-OG (PDB code 2QFX). The Mg(II) ion is modeled as a green sphere, and 2-OA and NADH are illustrated with
violet and green carbon atoms, respectively. (C) Stick diagram of the active site of SpHICDH bound to a GGG peptide (green carbons). Electron
density of the Fo-Fc simulated annealing omit map contoured to 2.0 r around the GGG peptide is shown in gray. Water molecules and hydrogen
bonds are shown as red spheres and green dashes, respectively. (D) Overlay of the active site of apo-SpHICDH (blue), GGG-bound SpHICDH
(orange), and TtHICDH (gray). Residues in SpHICDH and TtHICDH are labeled in blue and gray, respectively.
Structure of Homoisocitrate Dehydrogenase
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in their active sites [Fig. 2(D)].7 This observation is par-
ticularly interesting in that the structurally equivalent res-
idue in ICDHs is also a valine. ICDH specificity towards
its preferred substrate is instead governed by serine and
asparagine residues (Ser113 and Asn115 in EcICDH),
which form interactions with the C5 carboxylate of isoci-
trate [Supporting Information Fig. S2].25,27 The serine
residue is conserved in HICDHs, but the asparagine is an
isoleucine in yeast and archaeal HICDHs. Based on an
SpHICDH-isocitrate model [Fig. 2(A)], Val94 may form
van der Waals interactions to isocitrate, whereas in
TtHICDH the corresponding Arg85 could potentially
hydrogen bond to C5 carboxylate of isocitrate, equivalent
to the interaction of the asparagine residue in ICDHs.
Thus, this model offers a potential explanation for the
ability of TtHICDH to efficiently oxidize both citrate and
homocitrate. In summary, these observations suggest
potential routes to exploit structural variations between
the active sites of fungal and other b-hydroxyacid oxida-
tive decarboxylases to design HICDH-specific inhibitors.
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